2023
Glycemic control and diabetes complications across health status categories in older adults treated with insulin or insulin secretagogues: The Diabetes & Aging Study
Lipska K, Huang E, Liu J, Parker M, Laiteerapong N, Grant R, Moffet H, Karter A. Glycemic control and diabetes complications across health status categories in older adults treated with insulin or insulin secretagogues: The Diabetes & Aging Study. Journal Of The American Geriatrics Society 2023, 71: 3692-3700. PMID: 37638777, PMCID: PMC10872822, DOI: 10.1111/jgs.18565.Peer-Reviewed Original ResearchConceptsRisk of complicationsComplication riskPoor healthIntermediate healthOlder adultsGood healthRetrospective cohort studyEndocrine Society guidelinesIntegrated healthcare delivery systemType 2 diabetesProportional hazards modelHealth status categoriesHealthcare delivery systemMacrovascular eventsCohort studyGlycemic controlPrimary outcomeSevere hypoglycemiaSociety guidelinesClinical variablesInsulin secretagoguesHazards modelComplicationsCombined outcomeAging Study1356-P: Association of HbA1c with Diabetes Outcomes across Health Status Categories in Older Adults
LIPSKA K, HUANG E, LIU J, PARKER M, MOFFET H, GRANT R, LAITEERAPONG N, KARTER A. 1356-P: Association of HbA1c with Diabetes Outcomes across Health Status Categories in Older Adults. Diabetes 2023, 72 DOI: 10.2337/db23-1356-p.Peer-Reviewed Original ResearchComplication riskPoor healthIntermediate healthOlder adultsGood healthIntegrated healthcare delivery systemAssociation of HbA1cType 2 diabetesProportional hazards modelNational InstituteHealth status categoriesHealthcare delivery systemEligible patientsMacrovascular eventsSevere hypoglycemiaKidney diseaseClinical variablesDiabetes outcomesEndocrine SocietyAbbVie Inc.Hazards modelComplicationsHealth statusTwin healthPatients
2017
Pioglitazone and cardiovascular risk reduction
Perdigoto AL, Young LH, Inzucchi SE. Pioglitazone and cardiovascular risk reduction. Cardiovascular Endocrinology & Metabolism 2017, 6: 55-61. PMID: 31646121, PMCID: PMC6768516, DOI: 10.1097/xce.0000000000000110.Peer-Reviewed Original ResearchInsulin Resistance InterventionCV outcomesInsulin resistanceResistance InterventionImpact of thiazolidinedionesCardiovascular risk reductionGlucose-lowering drugsCardiovascular disease riskInsulin-resistant patientsType 2 diabetesCV complicationsMacrovascular eventsCV riskSecondary preventionResistant patientsStroke patientsStroke trialsPathophysiological abnormalitiesAntihyperglycemic agentsInsulin sensitivityDiabetes managementClinical practiceStroke resultsPatientsDisease risk
2016
Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes
Lipska KJ, Krumholz H, Soones T, Lee SJ. Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes. JAMA 2016, 315: 1034-1045. PMID: 26954412, PMCID: PMC4823136, DOI: 10.1001/jama.2016.0299.BooksConceptsRandomized clinical trialsIntensive glycemic controlGlycemic controlClinical trialsOlder adultsMicrovascular outcomesTreatment burdenPatient preferencesMost RCTsLarge randomized clinical trialsType 2 diabetes mellitusMajor macrovascular eventsStandard glycemic controlOptimal glycemic controlLower treatment burdenSurrogate end pointsHigh-quality evidenceType 2 diabetesLikelihood of benefitMajority of adultsGlycemic treatmentMacrovascular eventsDiabetes mellitusPatient factorsAging Patient
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply